We observed a correlation between elevated levels of pY105-PKM2 and poor prognosis in NSCLC patients, with the phosphorylated enzyme showing potential as a biomarker for disease progression and treatment outcomes. This evidence concerns the gene PKM and non-small cell lung carcinoma.